New combo therapy aims to shrink pancreatic tumors
NCT ID NCT06313970
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This study tests a new drug (QL1706) combined with standard chemotherapy, with or without another drug (bevacizumab), as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination can shrink tumors or control the disease. About 58 adults aged 18 to 75 who have not had prior treatment for their advanced cancer will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.